Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293056349> ?p ?o ?g. }
- W4293056349 endingPage "10871" @default.
- W4293056349 startingPage "10858" @default.
- W4293056349 abstract "Although various inhibitors have been employed to react with phenylacetaldehyde to form adducts and thus interrupt the formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), high concentrations of PhIP remain in the final system. It remains unknown whether other critical aldehyde or ketone intermediates are involved in the generation of PhIP, and scavenging these reactive carbonyls simultaneously may achieve higher inhibitory efficiency of PhIP. In this study, reactive carbonyls in a glucose/creatinine/phenylalanine model system were first identified by gas chromatography-mass spectrometry (GC-MS), and then the single and synergistic effects of nonprecursor amino acids (cysteine, methionine, proline, histidine, arginine, and leucine) on scavenging reactive carbonyls were investigated to find out promising combination partners. The obtained results showed that the concentrations of benzaldehyde and phenylacetaldehyde in the glucose/creatinine/phenylalanine model system reached 0.49 ± 0.01 and 6.22 ± 0.21 μg/mL, respectively. Heating these carbonyl compounds in the presence of creatinine resulted in the quantity of PhIP produced increasing linearly with the added quantity of benzaldehyde (r = 0.9733, P = 0.0002) and phenylacetaldehyde (r = 0.9746, P = 0.0002), indicating that both compounds are key intermediates for PhIP generation. Among the investigated amino acids, histidine produced the maximum inhibition of PhIP formation (78-99%) in the benzaldehyde/creatinine model system, and proline produced the maximum inhibition of PhIP formation (13-97%) in the phenylacetaldehyde/creatinine model system, where both compounds decreased PhIP formation in a dose-dependent manner. Histidine in combination with proline enhanced the inhibitory effect against PhIP formation at a low addition level, where the highest inhibitory efficiency was obtained using a 1:3 mass ratio of histidine to proline (2 mg/mL in total), reducing PhIP formation by 96%. These findings suggest that histidine-proline combinations can scavenge benzaldehyde and phenylacetaldehyde simultaneously, enhancing the suppression of PhIP formation." @default.
- W4293056349 created "2022-08-25" @default.
- W4293056349 creator A5002953504 @default.
- W4293056349 creator A5010479652 @default.
- W4293056349 creator A5012062174 @default.
- W4293056349 creator A5016450924 @default.
- W4293056349 creator A5033232209 @default.
- W4293056349 creator A5055823215 @default.
- W4293056349 creator A5056532825 @default.
- W4293056349 creator A5065133723 @default.
- W4293056349 creator A5065936826 @default.
- W4293056349 creator A5070425690 @default.
- W4293056349 creator A5071329405 @default.
- W4293056349 date "2022-08-25" @default.
- W4293056349 modified "2023-09-25" @default.
- W4293056349 title "Synergistic Inhibitory Effects of Selected Amino Acids on the Formation of 2-Amino-1-methyl-6-phenylimidazo[4,5-<i>b</i>]pyridine (PhIP) in both Benzaldehyde– and Phenylacetaldehyde–Creatinine Model Systems" @default.
- W4293056349 cites W1971184029 @default.
- W4293056349 cites W1980456933 @default.
- W4293056349 cites W1996320798 @default.
- W4293056349 cites W1998238468 @default.
- W4293056349 cites W2002413606 @default.
- W4293056349 cites W2031926526 @default.
- W4293056349 cites W2045590265 @default.
- W4293056349 cites W2048852237 @default.
- W4293056349 cites W2050351065 @default.
- W4293056349 cites W2056344806 @default.
- W4293056349 cites W2058852289 @default.
- W4293056349 cites W2078855755 @default.
- W4293056349 cites W2080606133 @default.
- W4293056349 cites W2080693309 @default.
- W4293056349 cites W2095080873 @default.
- W4293056349 cites W2259675120 @default.
- W4293056349 cites W2274617883 @default.
- W4293056349 cites W2276340822 @default.
- W4293056349 cites W2286530528 @default.
- W4293056349 cites W2538602696 @default.
- W4293056349 cites W2615201473 @default.
- W4293056349 cites W2755335441 @default.
- W4293056349 cites W2766637598 @default.
- W4293056349 cites W2766944025 @default.
- W4293056349 cites W2993164839 @default.
- W4293056349 cites W3010987920 @default.
- W4293056349 cites W3020760346 @default.
- W4293056349 cites W3028039335 @default.
- W4293056349 cites W3033894325 @default.
- W4293056349 cites W3043398749 @default.
- W4293056349 cites W3096883864 @default.
- W4293056349 cites W3134927130 @default.
- W4293056349 cites W3157474130 @default.
- W4293056349 cites W3175119773 @default.
- W4293056349 cites W3207529082 @default.
- W4293056349 cites W3214575509 @default.
- W4293056349 cites W4200539459 @default.
- W4293056349 cites W4224318790 @default.
- W4293056349 cites W4225395096 @default.
- W4293056349 cites W4281254863 @default.
- W4293056349 doi "https://doi.org/10.1021/acs.jafc.2c03122" @default.
- W4293056349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36007151" @default.
- W4293056349 hasPublicationYear "2022" @default.
- W4293056349 type Work @default.
- W4293056349 citedByCount "3" @default.
- W4293056349 countsByYear W42930563492022 @default.
- W4293056349 countsByYear W42930563492023 @default.
- W4293056349 crossrefType "journal-article" @default.
- W4293056349 hasAuthorship W4293056349A5002953504 @default.
- W4293056349 hasAuthorship W4293056349A5010479652 @default.
- W4293056349 hasAuthorship W4293056349A5012062174 @default.
- W4293056349 hasAuthorship W4293056349A5016450924 @default.
- W4293056349 hasAuthorship W4293056349A5033232209 @default.
- W4293056349 hasAuthorship W4293056349A5055823215 @default.
- W4293056349 hasAuthorship W4293056349A5056532825 @default.
- W4293056349 hasAuthorship W4293056349A5065133723 @default.
- W4293056349 hasAuthorship W4293056349A5065936826 @default.
- W4293056349 hasAuthorship W4293056349A5070425690 @default.
- W4293056349 hasAuthorship W4293056349A5071329405 @default.
- W4293056349 hasConcept C155647269 @default.
- W4293056349 hasConcept C161790260 @default.
- W4293056349 hasConcept C178790620 @default.
- W4293056349 hasConcept C185592680 @default.
- W4293056349 hasConcept C2777431362 @default.
- W4293056349 hasConcept C2777934754 @default.
- W4293056349 hasConcept C2779692420 @default.
- W4293056349 hasConcept C515207424 @default.
- W4293056349 hasConcept C55493867 @default.
- W4293056349 hasConceptScore W4293056349C155647269 @default.
- W4293056349 hasConceptScore W4293056349C161790260 @default.
- W4293056349 hasConceptScore W4293056349C178790620 @default.
- W4293056349 hasConceptScore W4293056349C185592680 @default.
- W4293056349 hasConceptScore W4293056349C2777431362 @default.
- W4293056349 hasConceptScore W4293056349C2777934754 @default.
- W4293056349 hasConceptScore W4293056349C2779692420 @default.
- W4293056349 hasConceptScore W4293056349C515207424 @default.
- W4293056349 hasConceptScore W4293056349C55493867 @default.
- W4293056349 hasFunder F4320321001 @default.
- W4293056349 hasIssue "35" @default.
- W4293056349 hasLocation W42930563491 @default.
- W4293056349 hasLocation W42930563492 @default.
- W4293056349 hasOpenAccess W4293056349 @default.